NCT01473004 |
Cabozantinib (MET inhibitor) vs Temozolomide |
II |
69 |
Recruiting |
Progression-free survival at 4 months |
NCT01585194 |
Ipilimumab + nivolumab (combination checkpoint blockade) |
II |
52 |
Recruiting |
Objective response rate |
NCT01814046 |
Adoptive T cell therapy + high dose IL-2 vs adoptive T cell therapy (T cell therapy) |
II |
57 |
Recruiting |
Objective response rate |
NCT01252251 |
Everolimus (mTOR inhibitor) + pasireotide (somatostatin analog) |
II |
25 |
Recruiting |
Clinical benefit rate |
NCT01587352 |
Vorinostat (histone deacetylase inhibitor) |
II |
40 |
Recruiting |
Objective response rate |
NCT01979523 |
Trametinib (MEK inhibitor) vs Trametinib + GSK2141795 (AKT inhibitor) |
II |
80 |
Recruiting |
Progression-free survival |
NCT02359851 |
Pembrolizumab (anti-PD1 antibody) |
II |
29 |
Recruiting |
Objective response rate |
NCT02273219 |
AEB071 (protein kinase C inhibitor) + BYL719 (PI3Kα inhibitor) |
I |
50 |
Recruiting |
Maximum tolerated dose |
NCT02363282 |
Glembatumumab vedotin (antibody-drug conjugate) |
II |
34 |
Not yet open |
Objective response rate |
NCT01730157 |
Radioembolization (Y90) with Ipilimumab (anti-CTLA4 antibody) |
0 |
12 |
Active, not recruiting |
Toxicity, hepatic response rate |